Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Memantine × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 7 Glioblastoma 3 Neoplasm Metastasis 2 Small Cell Lung Carcinoma 1 Recurrence 1 Neurotoxicity Syndromes 1 Neoplasms, Germ Cell and Embryonal 1 Melanoma 1 Lung Neoplasms 1 Gliosarcoma 1 Gastrointestinal Neoplasms 1 Epilepsy 1 Ependymoma 1 Craniopharyngioma 1 Cognitive Dysfunction 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Temozolomide 21 Bevacizumab 18 Cyclophosphamide 7 Lomustine 6 Irinotecan 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 4 Radiosurgery 4 Nivolumab 4 Filgrastim 4 Everolimus 4 Carboplatin 4 fludarabine phosphate 3 Vincristine 3 Sirolimus 3 IL13-PE38 3 Etoposide 3 Drug Therapy 3 Busulfan 3 Antilymphocyte Serum 3 thymoglobulin 2 sonidegib 2 ribociclib 2 pembrolizumab 2 paclitaxel-Angiopep-2 conjugate 2 olaparib 2 fluorodopa F 18 2 fludarabine 2 avapritinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01260467 2015-12-10

Memantine for Recurrent Glioblastoma

University of Rochester

Phase 2 Terminated

4 enrolled 3 charts

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡